BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 38199927)

  • 21. Urothelial Carcinoma Detection Based on Copy Number Profiles of Urinary Cell-Free DNA by Shallow Whole-Genome Sequencing.
    Ge G; Peng D; Guan B; Zhou Y; Gong Y; Shi Y; Hao X; Xu Z; Qi J; Lu H; Zhang X; Zhan Y; Li Y; Wu Y; Ding G; Shen Q; He Q; Li X; Zhou L; Ci W
    Clin Chem; 2020 Jan; 66(1):188-198. PubMed ID: 31811000
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urologic cancer in China.
    Pang C; Guan Y; Li H; Chen W; Zhu G
    Jpn J Clin Oncol; 2016 Jun; 46(6):497-501. PubMed ID: 27049022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long noncoding RNA in prostate, bladder, and kidney cancer.
    Martens-Uzunova ES; Böttcher R; Croce CM; Jenster G; Visakorpi T; Calin GA
    Eur Urol; 2014 Jun; 65(6):1140-51. PubMed ID: 24373479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Prognostic and predictive molecular markers for urologic cancers].
    Hartmann A; Schlomm T; Bertz S; Heinzelmann J; Hölters S; Simon R; Stoehr R; Junker K
    Urologe A; 2014 Apr; 53(4):491-500. PubMed ID: 24700189
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic and prognostic biomarkers of common urological cancers based on aberrant DNA methylation.
    Peng D; Ge G; Xu Z; Ma Q; Shi Y; Zhou Y; Gong Y; Xiong G; Zhang C; He S; He Z; Li X; Ci W; Zhou L
    Epigenomics; 2018 Sep; 10(9):1189-1199. PubMed ID: 30182734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serotonin used as prognostic marker of urological tumors.
    Jungwirth N; Haeberle L; Schrott KM; Wullich B; Krause FS
    World J Urol; 2008 Oct; 26(5):499-504. PubMed ID: 18581119
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nucleic acid-based marker approaches to urologic cancers.
    Veltri RW; Makarov DV
    Urol Oncol; 2006; 24(6):510-27. PubMed ID: 17138133
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetics of urological cancers.
    Maher ER
    Br Med Bull; 1994 Jul; 50(3):698-707. PubMed ID: 7987649
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers.
    Gulati S; Martinez P; Joshi T; Birkbak NJ; Santos CR; Rowan AJ; Pickering L; Gore M; Larkin J; Szallasi Z; Bates PA; Swanton C; Gerlinger M
    Eur Urol; 2014 Nov; 66(5):936-48. PubMed ID: 25047176
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-coding RNAs as biomarkers in liquid biopsies with a special emphasis on extracellular vesicles in urological malignancies.
    Zeuschner P; Linxweiler J; Junker K
    Expert Rev Mol Diagn; 2020 Feb; 20(2):151-167. PubMed ID: 31499007
    [No Abstract]   [Full Text] [Related]  

  • 31. Usefulness of PET/CT 18-FDG for the diagnosis and follow-up of urological, urothelial and kidney tumours.
    González-Ruiz de León C; García-Rodríguez J; Pérez-Castro N; Vigil-Díaz C; Pérez-Haro ML; Fernández-Gómez JM
    Actas Urol Esp (Engl Ed); 2019; 43(1):32-38. PubMed ID: 30100141
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The translational potential of microRNAs as biofluid markers of urological tumours.
    Fendler A; Stephan C; Yousef GM; Kristiansen G; Jung K
    Nat Rev Urol; 2016 Dec; 13(12):734-752. PubMed ID: 27804986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Practical Molecular Testing in a Clinical Genitourinary Service.
    Magers MJ; Cheng L
    Arch Pathol Lab Med; 2020 Mar; 144(3):277-289. PubMed ID: 31373513
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MicroRNA in prostate, bladder, and kidney cancer: a systematic review.
    Catto JW; Alcaraz A; Bjartell AS; De Vere White R; Evans CP; Fussel S; Hamdy FC; Kallioniemi O; Mengual L; Schlomm T; Visakorpi T
    Eur Urol; 2011 May; 59(5):671-81. PubMed ID: 21296484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Inheritance in neoplastic urogenital pathology].
    Alberti C
    Minerva Urol Nefrol; 2003 Sep; 55(3):173-83. PubMed ID: 14610436
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of C-reactive protein in urological cancers: a useful biomarker for predicting outcomes.
    Saito K; Kihara K
    Int J Urol; 2013 Feb; 20(2):161-71. PubMed ID: 22897628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review.
    Lamy PJ; Allory Y; Gauchez AS; Asselain B; Beuzeboc P; de Cremoux P; Fontugne J; Georges A; Hennequin C; Lehmann-Che J; Massard C; Millet I; Murez T; Schlageter MH; Rouvière O; Kassab-Chahmi D; Rozet F; Descotes JL; Rébillard X
    Eur Urol Focus; 2018 Dec; 4(6):790-803. PubMed ID: 28753865
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biological markers in urologic cancer.
    Lange PH; Winfield HN
    Cancer; 1987 Aug; 60(3 Suppl):464-72. PubMed ID: 3036331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The genetic landscapes of urological cancers and their clinical implications in the era of high-throughput genome analysis.
    Light A; Ahmed A; Dasgupta P; Elhage O
    BJU Int; 2020 Jul; 126(1):26-54. PubMed ID: 32306543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating tumour cells as biomarkers of prostate, bladder, and kidney cancer.
    Gorin MA; Verdone JE; van der Toom E; Bivalacqua TJ; Allaf ME; Pienta KJ
    Nat Rev Urol; 2017 Feb; 14(2):90-97. PubMed ID: 27872478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.